Funding from Government and International Organizations
Owing to increasing awareness about the potential value of vaccination, major government and international organizations have taken an active interest in curbing the preventable diseases and in vaccinating the maximum number of infants and adults. For instances, the Government of China offers free immunizations against more than ten diseases, including measles, hepatitis B, diphtheria pertussis, and tetanus. Various organizations like UNICEF, WHO, and other international organizations, play significant roles in the identification and distribution of potential vaccines. These organizations have also entered into collaborative agreements with the major players worldwide, helping in the growth of the market. Additionally, the prevalence of infectious diseases, innovative technology in vaccine development, and expanding awareness about preventive care are likely to drive the market for preventive vaccines globally.
Huge Capital Expenditures
There is an increasing demand for different types of vaccines that are expected to be introduced into the market in the future. However, R&D of vaccine takes a long period and it requires substantial capital investments. Vaccines have to undergo clinical trials before they can obtain approval for commercial release. At each stage of the clinical trial, a majority of vaccines are rejected. By the time the final product is approved for commercial use, huge capital has already been spent on the R&D process of vaccine development. This capital expenditure has an indirect effect on the final pricing of the product. The product becomes expensive in certain cases and is not affordable, especially in developing countries, as the per capita income in these countries is significantly lower. Additionally, adverse effects of few vaccines are further restricting the market.
North America is the Largest Market
North America is the largest market for global preventive vaccines owing to growing investment from key players in the development of innovative vaccines, and raising awareness about preventive care. In terms of growth, Asia-Pacific is the fastest growing region. The factors such as huge population base and government initiatives in creating awareness about vaccination programs in the region are anticipated to drive the market for preventive vaccines in the region.
Key Developments in the Market
- February 2018: GlaxoSmithKline, PLC (GSK) received European approval for the expanded indication for Fluarix Tetra (influenza vaccine) for ages six months and older.
- February 2018: The Four-strain vaccine, known as a quadrivalent vaccine, Influvac Tetra developed by Mylan will be available in New Zealand from April 2018.
Reasons to Purchase the Report
- To understand the current and future global preventive vaccines market in the developed and emerging regions.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- Identify the segment that is expected to dominate the market.
- Identify the regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1.1 Growing Prevalence of Infectious Diseases
6.1.2 Innovative Technology in Vaccine Development
6.1.3 Increased Funding from Government and International Organizations
6.1.4 Growing Awareness on Preventive Care
6.2.1 Risk of Adverse Effects
6.2.2 Huge Capital Expenditures
6.4 Key Challenges
7. Market Segmentation
7.1 By Vaccine Type
7.1.1 Live/Attenuated Vaccines
7.1.2 Inactivated Vaccines
7.1.3 Subunit Vaccines
7.1.4 Toxoid Vaccines
7.1.5 Conjugate Vaccines
7.1.6 Recombinant Vector Vaccines
7.1.7 DNA Vaccines
7.2 By Disease Indications
7.2.1 Pneumococcal Vaccines
7.3 By Geography
7.3.1 North America
18.104.22.168 United States
22.214.171.124 Rest of North America
126.96.36.199 United Kingdom
188.8.131.52 Rest Of Europe
184.108.40.206 Australia & New Zealand
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of the Middle East & Africa
7.3.5 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Emergent Biosolutions
9.4 GlaxoSmithKline PLC
9.5 Inovio Pharmaceuticals
9.6 Johnson & Johnson
9.7 Merck & Co.
9.8 Novartis AG
9.9 Pfizer, Inc.
9.11 List Not Exhaustive
10. Future of the Market